Understanding Polyomavirus and Merkel Cell Carcinoma (MCC): What It Means for Patients

Zaim Haq

What is Merkel Cell Carcinoma (MCC)?

Merkel Cell Carcinoma (MCC) is a rare but aggressive type of skin cancer. It often appears as a firm, painless, red or purple lump on sun-exposed areas of the skin, like the face, neck, arms, or legs. MCC is linked to two main causes: exposure to ultraviolet (UV) radiation and a virus called Merkel cell polyomavirus (MCPyV). This cancer is most common in older adults, individuals with lighter skin, and people with weakened immune systems. Understanding the role of MCPyV in MCC has helped researchers improve how they approach diagnosis, treatment, and prognosis[1].

What is Merkel Cell Polyomavirus (MCPyV)?

MCPyV is a common virus found on many people's skin, but in most cases, it does not cause any harm. However, in rare situations, MCPyV can play a key role in developing MCC. The virus can incorporate into an individual's DNA and trigger abnormal growth in Merkel cells, which are part of the skin and involved in touch sensation. This process can lead to cancer, especially in individuals with weakened immune systems or significant sun exposure[1, 2].

How Does MCPyV Affect MCC?

About 80% of MCC cases are linked to MCPyV, making it a major factor in the development of this cancer. However, the presence of MCPyV is not always a sign of a bad prognosis. Research has shown that MCC caused by MCPyV often has a better prognosis compared to MCC caused by UV damage alone. This is because MCC related to MCPyV tends to respond better to certain treatments, like immunotherapy, and may spread less aggressively[1, 3].

Prognosis and MCC

MCC is considered aggressive because it can grow quickly and spread to other parts of the body, such as lymph nodes, lungs, liver, or bones. Early detection is crucial for improving the chances of successful treatment. The prognosis for MCC depends on several factors, including:

Stage of Cancer at Diagnosis: Early-stage MCC, where the cancer is localized to the skin, has a much better prognosis compared to advanced stages where it has spread to lymph nodes or other organs[2].

Presence of MCPyV: Patients with MCPyV-positive MCC often have a better response to treatment and longer survival rates compared to those with UV-induced MCC[1,4].

Treatment Type: MCC is treated with a combination of surgery, radiation therapy, and immunotherapy. Immunotherapy, which helps the immune system fight the cancer, has shown promising results, especially in patients with MCPyV-positive MCC[4, 5].

What This Means for Patients

If you have been diagnosed with MCC, knowing whether it is linked to MCPyV can help guide your treatment and provide insights into your prognosis. Your doctor may order specialized tests to determine if MCPyV is present in your cancer. This information can help in selecting the best treatment options, such as immunotherapy, which has been particularly effective in MCPyV-positive MCC.

For patients, early detection and regular skin checks are critical. If you notice any unusual growths on your skin that are firm, fast-growing, or changing in color, consult a dermatologist immediately. Regular follow-ups after MCC treatment are also essential to monitor for recurrence or spread[3].

How Can You Reduce Risk?

While there is no guaranteed way to prevent MCC, you can lower your risk by protecting your skin from excessive sun exposure, avoiding tanning beds, and using sunscreen regularly. Maintaining a healthy immune system through a balanced diet, regular exercise, and addressing any underlying health conditions can also play a role in reducing your overall risk of MCC and other skin cancers[1, 2, 3].

Polyomavirus plays a significant role in the development and progression of many MCC cases, but it also offers hope for better treatment and prognosis. By understanding the connection between MCPyV and MCC, patients can work with their healthcare team to make informed decisions about their care. Early detection, effective treatment, and regular follow-ups are key to managing MCC and improving outcomes. If you have concerns about MCC or skin changes, don’t hesitate to contact your dermatologist or oncologist.

1. Tribble JT, Pfeiffer RM, Brownell I, Cahoon EK, Sargen MR, Shiels MS, Luo Q, Cohen C, Drezner K, Hernandez B, Moreno A, Pawlish K, Saafir-Callaway B, Engels EA, Volesky-Avellaneda KD. Merkel Cell Carcinoma and Immunosuppression, UV

Radiation, and Merkel Cell Polyomavirus. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4607. Epub ahead of print. PMID: 39602110.

2. Drum DL, Jallorina AG, Wan LS, Chang VT, Lee-Wong MF. Non-Genetic Biomarkers in Merkel Cell Carcinoma: Prognostic Implications and Predictive Utility for Response to Anti-PD-(L)1 Immune Checkpoint Inhibitors. Exp Dermatol. 2025 Jan;34(1):e70030. doi: 10.1111/exd.70030. PMID: 39791602.
3. Loke ASW, Lambert PF, Spurgeon ME. Current In Vitro and In Vivo Models to Study MCPyV-Associated MCC. Viruses. 2022 Oct 7;14(10):2204. doi: 10.3390/v14102204. PMID: 36298759; PMCID: PMC9607385.
4. Ma JE, Brewer JD. Merkel cell carcinoma in immunosuppressed patients. Cancers (Basel). 2014 Jun 27;6(3):1328-50. doi: 10.3390/cancers6031328. PMID: 24978436; PMCID: PMC4190543.
5. Yang JF, You J. Merkel cell polyomavirus and associated Merkel cell carcinoma. Tumour Virus Res. 2022 Jun;13:200232. doi: 10.1016/j.tvr.2021.200232. Epub 2021 Dec 15. PMID: 34920178; PMCID: PMC8715208.